Cat. #151122
Anti-Keratin6 [LL020]
Cat. #: 151122
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 3-4 weeks
Target: Keratin 6
Class: Monoclonal
Application: IHC ; IF ; WB
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Irene Leigh
Institute: Cancer Research UK, London Research Institute: Clare Hall Laboratories
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-Keratin6 [LL020]
- Research fields: Cell signaling and signal transduction
- Clone: LL020
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Molecular weight: 50 kDa
- Strain: Balb/c
- Reactivity: Human
- Host: Mouse
- Application: IHC ; IF ; WB
- Description: LL020 can be used as a proliferation marker.
- Immunogen: Carboxy terminal peptide
- Isotype: IgM
- Myeloma used: Sp2/0-Ag14
Target Details
- Target: Keratin 6
- Molecular weight: 50 kDa
- Target background: Keratins are a family of intermediate filament proteins that assemble into filaments through forming heterodimers of one type I keratin (keratins 9 to 23) and one type II keratin (keratins 1 to 8). Keratins demonstrate tissue and differentiation specific expression profiles. Keratins 6 is expressed in suprabasal keratinocytes of wounded epidermis and in acrosyringeal keratinocytes in normal skin.
Applications
- Application: IHC ; IF ; WB
Handling
- Format: Liquid
- Concentration: 0.9-1.1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Shipping at 4° C
References
- Hughes et al. 1996. Br J Dermatol. 134(2):247-56. PMID: 8746337.
- Keratin expression in pilosebaceous epithelia in truncal skin of acne patients.
- Markey et al. 1992. Br J Dermatol. 126(2):154-60. PMID: 1371396.
- Keratin expression in basal cell carcinomas.
